2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - New Orleans Theatre A
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Checkpoint Inhibitor, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Biological Processes, CHIP, Genomics, Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, T Cell Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

789 Lineage-informed autograft T-cell MRD predicts relapse after autologous stem cell transplantation in peripheral T-cell lymphoma: Results from the PETAL Consortium

Chandan Sanghera, MD, Kusha Chopra, BS2, Kristiana Nasto3, Josie Ford4, Ruwan Gunaratne, MD, PhD5, Aliyah R. Sohani6, Mark N Sorial, PharmD7, Emma DeMarco, BS8, Alexandra Lenart9, Maria J. Fernandez-Turizo, MD10, Caroline MacVicar11, Anna Rider12, Corben Yuwai Wong, BS13, Catherine Cho14, Ryan Burke15, Armando Nicolas Bastidas Torres, PhD16, Poorva Bindal, MD17, Sindha Thomas18, Eric Jacobsen, MD19, Mwanasha Merrill, MD20, Yumeng Zhang, MD21, Xiaohui Zhang, MD, PhD22, Robert Willim, MD23, Michael Leukam, MD, MS24, Jon E Arnason, MD25, Valentina Nardi26, Jia Ruan, MD, PhD27, Giorgio Inghirami, MD28, Jeffrey A Barnes, MD, PhD29, Yi-Bin A Chen, MD30, Steven McAfee, MD31, Ephraim P Hochberg, MD32, Makoto Iwasaki, MD, PhD33, Khyati Kariya34, Eric Minwei Liu, PhD35, Riya Bhattacharjee, BS36, Xuan Cheng, BS37, Govind Bhagat, MD38, Teresa Palomero39, Meredith Nichols, MD40, Esther Rheinbay, PhD41, Enrica Marchi, MD, PhD42, Stefan K Barta, MD43, Carrie van der Weyden, MD44, Tatyana Feldman, MD45, Christina Poh, MD46, Basem William, MD, MRCP(UK), FACP47, Estelle Verburgh, MD, PhD48, Zainab Mohamed49, Nathan Roberts, MD50, Danielle Blunt, MBBS51, Takashi Sakamoto, MD, PhD52, Bradley Haverkos, MD53, Mitsumasa Watanabe, MD54, Nora Bennani, MD55, Yun Kyoung Tiger, MD, PhD56, Jonathan Brammer, MD57, Pamela Allen, MD58, Deepa Jagadeesh, MD, MPH59, Maya deepti Srinivasan, MD, MSc60, John Mark L Sloan Jr, MD61, Lauren Shea, MD62, Harsh Rohit Shah, DO63, Sonali Smith, MD, FASCO64, Nazila Shafagati, MD65, Bhagirathbhai Dholaria, MD, FACP66, David Kurtz, MD, PhD67, Michael Khodadoust, MD PhD68, Salvia Jain, MD69
1 Stanford University, Stanford, California, United States
2 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
3 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
4 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
5 Stanford University, Stanford, California, United States
6 Harvard Medical School, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
9 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
12 Massachusetts General Hospital, Boston, Massachusetts, United States
13 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
14 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
15 Stanford University, Stanford, California, United States
16 Stanford University, Stanford, California, United States
17 University of Massachusetts Memorial Health Cancer Center, Worcester, Massachusetts, United States
18 University of Massachusetts Memorial Health Cancer Center, Worcester, Massachusetts, United States
19 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
20 Harvard Medical School, Boston, Massachusetts, United States, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
21 Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
22 Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
23 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
24 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
25 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
26 Harvard Medical School, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
27 Weill Cornell Medicine, New York, New York, United States
28 Weill Cornell Medicine, New York, New York, United States
29 Harvard Medical School, Boston, Massachusetts, United States, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
30 Harvard Medical School, Boston, Massachusetts, United States, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
31 Harvard Medical School, Boston, Massachusetts, United States, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
32 Harvard Medical School, Boston, Massachusetts, United States, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
33 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
34 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
35 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
36 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
37 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
38 Saint Louis University School of Medicine, St. Louis, Missouri, United States
39 Columbia University Medical Center, New York, New York, United States
40 Cleveland Clinic, Cleveland, Ohio, United States
41 Massachusetts General Hospital, Boston, Massachusetts, United States
42 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
43 University of Pennsylvania, Philadelphia, Pennsylvania, United States
44 Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
45 Hackensack Meridian Health Network, Hackensack, New Jersey, United States
46 City of Hope, Los Angeles, California, United States
47 OhioHealth, Columbus, Ohio, United States
48 University of Cape Town, Cape Town, South Africa
49 University of Cape Town, Cape Town, South Africa
50 University of Virginia Cancer Center, Charlottesville, Virginia, United States
51 Royal Adelaide Hospital, Adelaide, South Australia, Australia
52 Kyoto University Hospital, Kyoto, Japan
53 University of Colorado, Denver, Colorado, United States
54 Amagasaki General Medical Center, Amagasaki, Japan
55 Mayo Clinic, Rochester, Minnesota, United States
56 Mayo Clinic, Rochester, Minnesota, United States
57 Ohio State University Wexner Medical Center, Columbus, Ohio, United States
58 Emory University, Atlanta, Georgia, United States
59 Cleveland Clinic, Columbus, Ohio, United States
60 Boston Medical Center, Boston, Massachusetts, United States
61 Boston Medical Center, Boston, Massachusetts, United States
62 University of Alabama at Birmingham, Birmingham, Alabama, United States
63 Huntsman Cancer Institute, Salt Lake City, Utah, United States
64 University of Chicago, Chicago, Illinois, United States
65 University of Chicago, Chicago, Illinois, United States
66 Vanderbilt University Medical Center, Nashville, Tennessee, United States
67 Stanford University, Stanford, California, United States
68 Stanford University, Stanford, California, United States
69 Harvard Medical School, Boston, Massachusetts, United States, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Background
Autologous stem cell transplantation (ASCT) is commonly used as consolidation for peripheral T-cell lymphoma (PTCL), yet relapse rates remain high. Measurable residual disease (MRD) assessment in PTCL is challenging because of the lack of universally trackable markers and overlap between lymphoma-associated and clonal hematopoiesis (CH)-related mutations. To address this, we developed a personalized, tumor- and lineage-informed sequencing approach to determine whether MRD in the T-cell fraction of the infused autograft (autograft MRD) predicts relapse after ASCT.

Methods
51 patients with PTCL undergoing ASCT across 6 institutions were included, comprising 27 T-follicular helper (TFH) and 24 non-TFH lymphomas. Whole-exome sequencing (WES) of tumor tissue and matched B/NK-cell DNA identified patient-specific single-nucleotide variants (SNVs). Personalized panels incorporating WES-derived SNVs and canonical PTCL- and CH-associated variants were applied to flow-sorted T-cell, B/NK-cell, and myeloid fractions from apheresis products. Lineage-informed filtering compared variants across matched fractions to distinguish candidate lymphoma-associated variants from CH-related and other shared hematopoietic variants. Variants detected in non–T-cell fractions were removed unless enriched in T-cells, generating a lineage-filtered variant set for autograft MRD assessment. Longitudinal plasma and paired diagnostic-relapse tissue samples were evaluated in available subsets.

Results
WES identified a median of 28 candidate SNVs per patient (range, 7–214). Targeted sequencing recovered trackable SNVs in all 51 patients, with a median of 33 (range, 8–172) per patient. Canonical PTCL- and CH-associated variants comprised a median of 5.6% of trackable variants, and 7 patients (13.7%) lacked canonical variants. Personalized variants improved the theoretical limit of detection by a median of 10.8-fold (range, 2.7–146.9).

Shared variants were identified across ≥2 apheresis fractions in 39 patients (76.5%), including T-cell–involving variants in 38 (74.5%). Filtering removed all T-cell–involving shared variants in 26 of 38 patients (68.4%), while retaining T-cell-restricted or enriched lymphoma-associated variants.

With a median follow-up of 43.5 months, autograft T-cell MRD prior to filtering was associated with inferior PFS (HR 2.87, 95% CI 1.15–7.20, p=0.019). After lineage-informed filtering, MRD was detected in 30 patients and not detected in 21, with stronger relapse-risk stratification (HR 5.32, 95% CI 1.83–15.51, p=0.00063). Relapse occurred in 22 of 30 patients with detectable MRD (73.3%) versus 4 of 21 without detectable MRD (19.0%, p=0.00019). This association was observed in TFH (HR 4.90, p=0.023) and non-TFH lymphomas (HR 6.97, p=0.0050) and was retained after adjustment for PIT score (adjusted HR 5.53, 95% CI 1.62–18.84, p=0.0062).  At pre-ASCT response assessment, 41 patients were in complete remission (CR), 9 were in partial remission (PR), and 1 was unknown. Among patients in CR, relapse occurred in 18 of 23 with detectable MRD versus 3 of 18 without detectable MRD (p=0.00013). Among patients in PR, MRD was detected in 6 of 9; relapse occurred in 4 of 6 with detectable MRD and 1 of 3 without detectable MRD (p=0.52). 

In 24 patients who underwent longitudinal plasma collection, 235 samples were analyzed. Circulating tumor DNA (ctDNA) MRD was detected in 44 of 48 post-ASCT samples collected during active disease (91.7%) and preceded relapse in 4 of 5 evaluable patients, with a median lead time of 1.87 months. Across 9 paired diagnostic-relapse comparisons, SNVs retained from diagnosis to relapse had higher normalized allele frequencies than SNVs detected at one time point only. Furthermore, 43.2% of SNVs present at diagnosis and relapse were detected in the autograft T-cell fraction, compared with 10.5% of diagnosis-only SNVs (p=1.37 × 10−11), supporting their use as longitudinal MRD targets.

Conclusions
Personalized, lineage-informed sequencing reduces confounding hematopoietic background variants and enables broadly applicable mutation-based MRD assessment in PTCL. Lineage-informed autograft T-cell MRD stratified post-ASCT relapse risk, including among patients in end-of-treatment CR prior to ASCT, and remained associated with PFS after adjustment for PIT score. These findings support prospective validation of autograft and longitudinal ctDNA MRD to inform pre-ASCT risk stratification and disease surveillance in PTCL.

Chandan Sanghera, MD: No relevant conflicts of interest to declare.